Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the delivery of a cannabis shipment worth nearly C$8 million, in one of the largest single shipments of cannabis that Israel has received.
The sale is a significant step in advancing the Company’s international medical business, a key strategic priority for Aurora as a global cannabis company. With leadership in both Canada and Europe, Aurora is uniquely positioned to be a partner of choice in countries like Israel, where THC recreational markets are expected to be around the corner, and non-THC cannabinoids, such as CBD, are advancing toward legalization.
“We are excited about the evolution of the cannabis industry in Israel and commend the Ministry of Health and the Israeli Medical Cannabis Agency for ensuring thoughtful regulation of cannabis, in the best interest of Israeli cannabis patients,” says Miguel Martin, Chief Executive Officer of Aurora. “We look forward to continuing to provide high-quality cannabis to Israel, as part of our strategy to expand our medical cannabis portfolio in key international markets.”
The Company, which has a strategic supply agreement with Cantek Global Ltd., one of Israel’s leaders in the medical cannabis field, intends to supply a minimum of 4,000 kg of bulk dried flower annually to Israel.
